Services >> Cell Based Phenotypic >> Immunology

Immunology

Sidebar Image

undefined

The ImmunoSignal™ platform provides a suite of services to understand the immune response to your therapeutic. Our in vitro solutions for discovery pharmacology and preclinical research include multiplexed cytokine analysis and flow cytometry techniques, allowing simultaneous monitoring of pro- and anti-inflammatory markers.

We conduct assays using a unique bank of Peripheral Blood Mononuclear Cells (PBMCs) from donors of diverse ethnical backgrounds, offering genetic diversity.  These primary cell banks are from single human donors for a consistent cellular source for cytokine secretion assyes, which is useful for maintaining cross data integrity. Monocytes, T-cells and B-cells have also been isolated from these banks for proliferation and cytokine studies.

Enjoy tailored made solutions for your immunological studies by using our custom services. We can use your specified cell lines or sub-cellular components isolated from white blood cells or design a panel to meet your specific needs.

Whether you decide on an off-the-shelf solution or a highly customized assay, Eurofins has the immunology solution you need to further your drug development program.

undefined

Advantage of ImmunoSignal™ services:

  • Reliable and predictive with access to a large bank of well-characterized human cells
    • Multiple human donors offering genetic diversity
    • Characterized for sensitivity and robustness in cytokine or adhesion protein release levels
  • Expert scientific and technical support for data interpretation
  • Flexible, custom immune marker panels and testing conditions available
    •  Access relevant cellular models and biological fluids from animal studies.
  • Quality, fully validated and quality-controlled
  • Multiplex analysis and flow cytometry techniques to detect bioananlytes and cellular proliferation and viability

 

ImmunoSignal™ services : viewourcatalog
  • Cytokine Storm panel
    • Identify potentially life threating acute immune responses early in large molecule development
  • T-Cell functional panels    
    • Inflammation inhibition - screen for immunosuppressive or anti-inflammatory agents
    • Inflammation stimulation - test for potential immunogenicity of biologics
    • Th17 activation assays - screen for anti-inflammatory agents for autoimmune disease
  • Macrophage / monocyte panels   
    • Inflammation inhibition - screen for immunosuppressive or anti-inflammatory agents
    • Inflammation stimulation assays - test for potential immunogenicity of biologics
  • T-Cell Receptor (TCR) activation assay
    • Inflammation inhibition (Jurkat model) - screen for anti-inflammatory agents with a TCR related mechanism of action
  • Cardiovascular inflammation
    • Inflammation inhibition (HUVEC model) - identify anti-inflammatory agents with a mechanism of action of preventing cytokine release from endothelial tissue
  • Toll-like receptors (TLRs) panels
    • TLR activation - screen for agonists that may have potential to treat or prevent infectious and neoplastic diseases.
    • TLR inhibition - screen for antagonists to treat inflammatory conditions, including sepsis, skin diseases, rheumatoid arthritis and systemic lupus erythematosus.

PBMC donors

Peripheral Blood Mononuclear Cells (PBMC) is a qualified in vitro model for cytokine secretion and estimation of immune response. We use large and fully characterized batches of cryopreserved PBMCs to ensure repeatability on every screen.

ImmunoSignal™ human PBMC bank :

  • Large bank of PBMC ensures similar response, every time
    • Each leukapheresis give over 100 plates worth of assays
    • PBMC bank includes diverse ethnicity
  • All models are tested for functional expression with pro- and anti-inflammatory agents 
  • Access to other preclinical PBMCs, including rat, mouse, non-human primate, beagle, etc....



Table 1.
 Human PBMC donors: age, ethnicity and gender

 

Donor 1

Donor 2

Donor 3

Donor 4

Donor 5

Donor 6

Donor 7

Donor 8

Donor 9

Gender

Male

Female

Female

Male

Male

Male

Male

Male

Male

Age Group

20-30

40-50

30-40

40-50

20-30

20-30

30-40

50-60

20-30

Ethnicity

Caucasian

Caucasian

Caucasian

African-American

East Asian

South American
Non-Latino

Mixed
South Asian

   



Table 2.
 Human PBMC Donor phenotyping

Marker

Gate

Target

Donor 1

Donor 2

Donor 3

Donor 4

Donor 5

Donor 6

Donor 7

Donor 8

Donor 9

Donor 10

CD45+CD3+

CD45+

T-cells (CD3+)

61.9

64.2

62.3

69.2

50.0

58.0

55.3

69.6

55.6

37.8

CD4+

CD45+CD3+

T-helper (CD4+)

26.6

17.5

25.5

22.2

13.3

26.5

29.7

34.3

34.8

20.0

CD8+

CD45+CD3+

T-cytotoxic (CD8+)

22.8

32.8

20.2

25.2

26.6

24.6

16.7

27.7

14.9

14.0

CD45+CD3-

CD45+

Non-T-cells (CD3-)

38.2

35.9

37.9

31.0

50.0

42.2

44.9

30.5

44.4

62.0

CD14+

CD45+CD3-

Monocytes and macrophages (CD14+)

17.4

15.4

17.6

10.2

20.3

14.4

10.5

9.6

18.2

33.5

CD19+

CD45+CD3-

B-cells (CD19+)

6.6

8.7

8.8

4.3

9.8

6.9

14.4

9.0

13.2

6.0

CD16+CD56+

CD45+CD3-

NK (CD16+CD56+)

4.6

3.4

2.8

1.3

7.0

6.3

6.8

3.0

2.0

5.6

   

Others

9.6

8.4

8.8

15.3

12.9

14.6

13.1

8.9

10.9

16.9